Six out of six evaluable patients in Tenaya Therapeutics’ MyPEAK-1 trial achieved reductions in at least one echocardiographic measure of hypertrophy after receiving TN-201, a gene therapy targeting the root genetic cause of MYBPC3-associated hypertrophic cardiomyopathy. That number matters because existing approved therapies for obstructive HCM address the hemodynamic consequences of the disease, not the underlying mutation. TN-201 is attempting something structurally different: deliver a functional MYBPC3 gene and let the myocardium remodel itself.
The interim data covering 26 to 104 weeks across two dose cohorts (3E13 and 6E13 vg/kg) also showed improvements in symptom burden across all six evaluable patients, as measured by NYHA class and KCCQ scores, with no dose-limiting toxicities and full tapering off immunosuppressives. The RIDGE-1 trial for TN-401, targeting PKP2-associated arrhythmogenic right ventricular cardiomyopathy, added a particularly clean signal: premature ventricular contractions fell by a mean of 64% from baseline across all six dosed patients, and two patients with high burdens of non-sustained ventricular tachycardia saw reductions as early as week 20. Both programs have now completed the enrollment needed to characterize dose response for late-stage planning. Both also hold EMA PRIME designation, which provides enhanced regulatory dialogue and is designed to optimize development plans for medicines addressing unmet medical needs, though it is not itself an expedited approval pathway.
The company’s financial position is the context that shapes every one of these milestones. Cash runway extends only through Q3 2027, propped up in part by a $10 million upfront payment from an Alnylam collaboration that also carries up to $1.1 billion in potential milestones. Tenaya shed its manufacturing facility lease and is relying on a contract development manufacturing organization for future clinical supply. That is a lean operation for a company simultaneously running two Phase 1b/2 gene therapy trials, preparing pivotal trial submissions for both, and pushing a small-molecule HDAC6 inhibitor (TN-301) toward a Phase 2 start in the second half of 2027 across indications including HFpEF and Duchenne muscular dystrophy.
The single number to track now is what comes out of fourth-quarter 2026 regulatory discussions on pivotal trial design for both TN-201 and TN-401. Trial design determines sample size, duration, and capital requirements, and those three variables will decide whether the current runway is a runway or a cliff. If FDA alignment on a registrational path arrives before cash becomes critical, the data Tenaya has in hand is genuinely competitive. If it does not, the Alnylam milestone structure and the manufacturing asset sale look less like efficiency and more like preparation for a difficult 2027.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
